[One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients].

CONCLUSIONS: The authors demonstrated that the one-year persistence of ACEI/CCB FDCs was significantly different in hypertensive patients. Ramipril/amlodipine FDC was more advantageous for patient adherence. Orv Hetil. 2019; 160(9): 343-348. PMID: 30798621 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30798621?dopt=Abstract

Source: Orvosi Hetilap - February 27, 2019 Category: General Medicine Authors: Simonyi G, Ferenci T, Finta E, Igaz I, Balogh S, Gasparics R, Medvegy M Tags: Orv Hetil Source Type: research